Distinct differences of non-canonical IDH mutant gliomas


  • Patients with non-canonical isocitrate dehydrogenase (IDH)-mutant gliomas have distinct radiological and histological features compared with the more common canonical IDH1 p.R132H mutant gliomas.

Why this matters

  • Even though the WHO glioma classification (2016) suggests that the type of IDH mutation has no impact on diagnosis, approximately 10% of gliomas have non-canonical IDH mutations in the IDH1 or IDH2 genes.

  • Limited studies have described patient characteristics of non-canonical IDH mutant gliomas.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.